Scientific literature
Colognesi M, Gabbia D, Signor A, Sarill M, Centofanti L, Rinaldi A, Cascione L, Nunziata S, Banzato M, Mattarei A, Finzi G, Sonda S, Pendin D, Zanotto I, Comai S, Pasut G, Alajati A, Saponaro M, Bucciarelli L, Lunati ME, Guarato G, Goggi I, La Rosa S, Morano C, Paroni RC, Dei Cas M, Daniele G, Gentilucci M, Pappagallo M, Alimonti A, Manfredi PL, Folli F, De Martin S. Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms. Pharmacological Research. 2026 Feb;224:108080. DOI: 10.1016/j.phrs.2025.108080
Signor A, Colognesi M, Gabbia D, Zanotto I, Frion-Herrera Y, Comai S, Mattarei A, Pasut G, Folli F, Pappagallo M, Manfredi P, De Martin S. Direct effects of psilocybin on serotonin receptors regulate lipid accumulation in hepatic cells and adipocytes. Digestive and Liver Disease. 2025 eb;57(Suppl 1):S71. DOI: 10.1016/j.dld.2025.01.134
De Martin S, Gabbia D, Colognesi M, Rinaldi A, Cascione L, Zanotto I, Sayaf K, Comai S, Mattarei A, Banzato M, Pasut G, Folli F, Centofanti L, Traversa S, Pappagallo M, Manfredi PL. Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD. Digestive and Liver Disease. 2024 Feb;56(Suppl 1):S1. DOI: 10.1016/j.dld.2024.01.104
Colognesi M, Gabbia D, Signor A, Comai S, Mattarei A, Pasut G, Folli F, Centofanti L, La Rosa S, Finzi G, Pappagallo M, Manfredi P, De Martin S. Beneficial effect of the combination psilocybin–semaglutide in a murine model of Steatotic Liver Disease. Digestive and Liver Disease. 2025 Feb;57(Suppl 1):S71. DOI: 10.1016/j.dld.2025.01.135
Colognesi M, Gabbia D, Signor A, Comai S, Mattarei A, Pasut G, Centofanti L, La RosaS, Finzi G, Folli F, Pappagallo M, Manfredi P, De Martin S. Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD. Poster presentation. Journal of Hepatology. 2025 May;82(Supply 1):S606–S607. DOI: 10.1016/S0168-8278(25)01632-0
De Martin S. Semaglutide and Psilocybin in a Mouse Model of Obesity, Steatotic Liver Disease and Type 2 Diabetes. Presentation. Obesity Week; 3–6 Nov 2024; San Antonio, TX, USA
Sonda S, Pendin D, Comai S, De Martin S, Manfredi P, Mattarei A. Emerging mechanisms of psilocybin-induced neuroplasticity. Trends in Pharmacological Sciences. 2025 Nov;46(11):1130–1143. DOI: 10.1016/j.tips.2025.08.012
Nasini S, Tidei S, Barzon B, Casile A, De Martin S, Banzato M, Mattarei A, Folli F, Pappagallo M, Manfredi PL, Comai S. Psilocybin microdosing and cognitive flexibility: behavioral, inflammatory, and neuroplastic insights. Poster presentation. Workshop “The Neuroscience of Cognitive and Behavioural. Flexibility: from Function to Dysfunction”; 6 Jan 2025; Milan, Italy
Nasini S, Barzon B, Tidei S, Casile A, Xausa S, Benvenuti V, Cambiaghi M, De Martin S, Banzato M, Mattarei A, Pappagallo M, Manfredi P, Comai S. Chronic microdosing with psilocybin as a novel strategy to promote visual recovery after occipital stroke. Poster presentation. BraYn Conference; 29–31 Oct 2025; Turin, Italy.
Nasini S, Barzon B, Tidei S, Casile A, Xausa S, Benvenuti V, Cambiaghi M, De Martin S, Banzato M, Mattarei A, Pappagallo M, Manfredi P, Comai S. Chronic administration of sub-perceptual psilocybin enhances visual rehabilitation post-occipital stroke in mice. Oral presentation. SIF Young Meeting; 30 Nov–2 Dec 2025; Bologna, Italy
Nasini S, Barzon B, Cambiaghi M, De Martin S, Mattarei A, Banzato M, Pappagallo M, Manfredi P, Comai S. Chronic non-psychedelic psilocybin promotes visual recovery after occipital stroke. Oral presentation. 21st National Congress of the Italian Society for Neuroscience; 10–13 Sep 2025; Pisa, Italy